Less than a month after the federal multidistrict litigation (MDL) involving Biomet hip lawsuits held its first court hearing, the judge overseeing the proceedings appointed a plaintiff’s steering committee.

U.S. District Judge, Robert L. Miller issued the order on Dec. 5, just a few weeks after the status conference was completed, marking the next step in the proceedings of the Biomet hip replacement litigation, which involves claims filed over the controversial Biomet Magnum M2a hip implant.

According to court records, the order was issued at the request of attorneys, who suggested that Judge Miller appoint a plaintiff’s steering committee at the Nov. 16 court hearing. . Biomet hip lawsuits involved in this federal MDL are currently pending in the U.S. District Court for the Northern District of Indiana.

Biomet Hip Lawsuits

There are almost one hundred Biomet hip lawsuits pending in federal court, with another 400 waiting to be filed by attorneys who attended the November hearing, reports say. Court reports surmise that the number of Biomet hip lawsuits will soon total one thousand.

This federal MDL was created Oct. 2 by the U.S. Judicial Panel on Multidistrict Litigation, after the organization became aware of eight Biomet hip lawsuits pending in federal court, and another 57 potential claims awaiting review in U.S. state courts.

Biomet Hip Replacement Litigation

Plaintiffs who have filed Biomet hip lawsuits allege the implant, which is comprised of chromium and cobalt, caused them to suffer unexplained hip pain, soft tissue damage and inflammation, difficulty walking and/or standing and metallosis—a condition that develops when the pieces of the device rub together and shed metallic debris into the patient’s bloodstream.  Symptoms of metallosis include pain, swelling and even pseudo tumors, which has forced patients to undergo revision surgeries to remove the implant.

The rise in Biomet hip lawsuits may be starting to resonate in Biomet Inc.’s financial sector. According to a Bloomberg Businessweek report on Oct. 11, the company experienced a 1 percent drop in revenue from its hip and knee implants.  This was specifically due to lower sales volumes, the article said.

Published December 13, 2012 by